Tiered And Backlog Generic User Fees Are Possible But Create Challenges For FDA
Executive Summary
Ideas for tiered and backlog user fees for generic drug applications remain possibilities, but appear to face significant hurdles to becoming part of any program because of administrative and other issues that would come with them.
You may also be interested in...
GDUFA Talks: FDA Reminds Industry The Program Is Generic-Only
Generic drug user fee negotiations began with a reminder that components of the program will not apply to other regulated drug sectors.
GDUFA Talks: FDA Reminds Industry The Program Is Generic-Only
Generic drug user fee negotiations began with a reminder that components of the program will not apply to other regulated drug sectors.
Generic User Fees: FDA Reaches Out To More Trade Groups; Plan Could Mix Inspection and Application Fees
FDA continues to mull inspection- and application-based proposals for a generic drug user fee, but before beginning negotiations it wants comments from a wider breadth of the industry.